A New Combination Therapy for a Rare Form of Leukemia
The FDA approved an oral combination of an epigenetic therapy along with an enzyme inhibitor to treat certain adults...
Progress Against Cancer
The FDA approved an oral combination of an epigenetic therapy along with an enzyme inhibitor to treat certain adults...
The FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain...
The new therapeutic was approved by the FDA for treating patients whose leukemia tests positive for a mutation in...
The FDA decision means tisagenlecleucel (Kymriah) is now approved for certain types of non-Hodgkin lymphoma and acute lymphoblastic leukemia....
Researchers identified mutations in leukemias that may make them amenable to FDA-approved ALK inhibitors Using genomic sequencing, researchers identified...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now